Publications

Search
Found 80 results
Filters: Author is Morgan,S. G.  [Clear All Filters]
Atlas
Morgan SG, Cunningham C, Hanley G, Mooney D. BC Rx Atlas 2nd Edition (2009). 2nd Edition. UBC Centre for Health Services and Policy Research; 2009.
Morgan SG, Cunningham C, Hanley G, Mooney D. British Columbia Medical and Hospital Atlas. Vancouver (BC): UBC Centre for Health Services and Policy Research; 2009.
Morgan SG, Schaub P, Mooney D, Lam JM, Caetano PA. British Columbia Rx Atlas, 1st Edition. Vancouver (BC): UBC Centre for Health Services and Policy Research; 2005.
Morgan SG, McMahon M, Lam JM, Mooney D, Raymond CB. Canadian Rx Atlas, 1st edition. UBC Centre for Health Services and Policy Research; 2005.
Morgan SG, Raymond CB, Mooney D, Martin D. The Canadian Rx Atlas, 2nd Edition. UBC Centre for Health Services and Policy Research; 2008.
Morgan SG, Smolina K, Mooney D, Raymond C, Bowen M, Gorczynski C, et al. Canadian Rx Atlas, 3rd Edition. 3rd ed. Centre for Health Services and Policy Research; 2013.
Journal Article
Raymond CB, Morgan SG, Caetano PA. Antidepressant utilization in British Columbia from 1996 to 2004: increasing prevalence but not incidence. Psychiatric services (Washington, D.C.)Psychiatr.Serv.. 2007;58(1):79-84.
Morgan SG, McMahon M, Greyson D. Balancing health and industrial policy objectives in the pharmaceutical sector: lessons from Australia. Health policy (Amsterdam, Netherlands)Health Policy. 2008;87(2):133-145.
Morgan SG. Booming prescription drug expenditure: a population-based analysis of age dynamics. Medical careMed.Care. 2005;43(10):996-1008.
Morgan SG, Hanley G, Raymond C, Blais R. Breadth, Depth and Agreement Among Provincial Drug Formularies in Canada . Healthcare Policy. 2009;4(4):e162-e184.
Morgan SG, Hanley G, Raymond C, Blais R. Breadth, Depth and Agreement among Provincial Formularies in Canada. Healthcare policy = Politiques de santeHealthc.Policy.. 2009;4(4):e162-84.
Morgan SG, Bassett KL, Wright JM, Evans RG, Barer ML, Caetano PA, et al. "Breakthrough" drugs and growth in expenditure on prescription drugs in Canada. BMJ (Clinical research ed.)BMJ. 2005;331(7520):815-816.
Morgan SG. Canadian prescription drug costs surpass 18 billion dollars. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienneCMAJ. 2005;172(10):1323-1324.
Abelson J, Mendelsohn M, Lavis JN, Morgan SG, Forest PG, Swinton M. Canadians confront health care reform. Health affairs (Project Hope)Health.Aff.(Millwood). 2004;23(3):186-193.
Morgan SG, McMahon M, Mitton C. Centralising drug review to improve coverage decisions: economic lessons from (and for) Canada. Applied health economics and health policyAppl.Health.Econ.Health.Policy.. 2006;5(2):67-73.
Morgan SG, McMahon M, Mitton C, Roughead E, Kirk R, Kanavos P, et al. Centralized drug review processes in Australia, Canada, New Zealand, and the United kingdom. Health affairs (Project Hope)Health.Aff.(Millwood). 2006;25(2):337-347.
Hanley GE, Morgan SG. Chronic catastrophes: exploring the concentration and sustained nature of ambulatory prescription drug expenditures in the population of British Columbia, Canada. Social science & medicine (1982)Soc.Sci.Med.. 2009;68(5):919-924.
Hanley G, Morgan SG. Chronic Catastrophes: Exploring the Concentration & Sustained Nature of Ambulatory Rx Drug Expenditures in the Population of BC. Social Science and Medicine. 2009.
McMahon M, Morgan SG, Mitton C. The Common Drug Review: a NICE start for Canada? Health policy (Amsterdam, Netherlands)Health Policy. 2006;77(3):339-351.
Morgan SG, Hanley G, Greyson D. Comparing tiered formularies and reference pricing policies: A systematic review. Open Medicine. 2009;3(3).
Morgan SG, Grootendorst P, Lexchin J, Cunningham C, Greyson D. The cost of drug development: a systematic review. Health Policy. 2011;100(1):4-17.
Morgan SG, Kennedy J. Cost-Related Prescription Nonadherence in the United States and Canada. Clinical Therapeutics. 2009;31(1):213-219.
Law M., Kawasumi Y, Morgan SG. Despite Law, Fewer Than One In Eight Completed Studies Of Drugs And Biologics Are Reported On Time On Clinical Trials. Health Affairs. 2011;30(12):2338-2345.
Law M., Kawasumi Y, Morgan SG. Despite law, fewer than one in eight completed studies of drugs and biologics are reported on time on ClinicalTrials.gov. Health Affairs. 2011;30(12):2338-2345.
Morgan SG. Direct-to-consumer advertising and expenditures on prescription drugs: a comparison of experiences in the United States and Canada. Open medicine : a peer-reviewed, independent, open-access journalOpen Med.. 2007;1(1):e37-45.

Pages